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The aim of our study was to determine the influence of inhibition of insulin-
regulated aminopeptidase/oxytocinase (IRAP) on glucose tolerance and metabolism
of skeletal muscle and visceral adipose tissue in obese Zucker rats. Obese Zucker
rats administered with IRAP inhibitor–HFI-419 at a dose of 29 µg/100 g BW/day by
osmotic minipumps implanted subcutaneously for 2 weeks. Two-hour intraperitoneal
glucose tolerance test (ipGTT) was performed in fasting rats. Plasma oxytocin levels
were measured by enzyme immunoassay after plasma extraction. In the musculus
quadriceps and epididymal adipose tissue, the expression of factors affecting tissue
oxidative status and metabolism was determined by real-time qPCR and/or Western blot
analysys. The plasma and tissue enzymatic activities were determined by colorimetric
or fluorometric method. Circulated oxytocin levels in obese animals strongly tended to
increase after HFI-419 administration. This was accompanied by significantly improved
glucose utilization during ipGTT and decreased area under the curve (AUC) for glucose.
In skeletal muscle IRAP inhibitor treatment up-regulated enzymes of antioxidant defense
system – superoxide dismutase 1 and 2 and improved insulin signal transduction
pathway. HFI-419 increased skeletal muscle aminopeptidase A expression and activity
and normalized its plasma levels in obese animals. In epididymal adipose tissue, gene
expression of markers of inflammation and adipocyte hypertrophy was down-regulated
in obese rats after HFI-419 treatment. Our results demonstrate that IRAP inhibition
improves whole-body glucose tolerance in insulin-resistant Zucker fatty rats and that
this metabolic effect of HFI-419 involves ameliorated redox balance in skeletal muscle.
Keywords: obesity, insulin resistance, insulin-regulated aminopeptidase, IRAP, HFI-419
INTRODUCTION
Obesity comprises one of the key risk factors for the metabolic syndrome and contributes to the
development of insulin resistance and subsequently to type two diabetes mellitus, atherogenic
dyslipidemia and cardiovascular disease (Ritchie and Connell, 2007). The high fat intake is
associated with oxidative stress and activation of pro-inflammatory transcription factors (Ritchie
and Connell, 2007). One of the most deleterious effects of obesity is the deposition of lipids
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in non-adipose tissues and hyperlipidenia-induced reactive
oxygen species production leading to mitochondrial dysfunction
in insulin-responsive tissues which might promote inhibition
of insulin action (Di Meo et al., 2017). The Zucker fatty rat
represents a well-established model of human obesity and insulin
resistance. Obesity in this animal model is a consequence of
spontaneous mutation (fa) in the gene encoding the leptin
receptor resulting in hyperphagia (Phillips et al., 1996).
Insulin-regulated aminopeptidase (IRAP; leucyl-cystinyl
aminopeptidase; oxytocinase), encoded by a Lnpep gene, has a
broad distribution including skeletal muscle and white adipose
tissue (Chai et al., 2004). IRAP is predominantly present
in cytosolic vesicles together with the glucose transporter
(GLUT4), from where they translocate to the plasma membrane
upon insulin stimulation. The IRAP is a membrane bound
protein belonging to the M1 family of aminopeptidases and
its substrates include vasopressin and oxytocin (Chai et al.,
2004). IRAP has been proposed as the surrogate marker of
insulin-regulated vesicular traffic along with GLUT4 since
the presence of IRAP is required for maintaining normal
insulin-dependent translocation as well as forming an insulin-
responsive vesicular compartment at the plasma membrane
(Gross et al., 2004).
It has been found out that obesity in Zucker rats and also ob/ob
mice is associated with a high plasma aminopeptidase A (AP-
A) activity, the enzyme responsible for generating angiotensin
III, thus contributing to blood pressure control (Morais et al.,
2017; Lory et al., 2019). In our previous study we have shown that
increased AP-A release from the skeletal muscle in obese Zucker
rats significantly contributes to elevated plasma AP-A activity
(Lory et al., 2019).
Recently, we have shown that obesity is accompanied by
marked reduction of plasma oxytocin level in Zucker fatty rats
caused by increased peptide degradation by liver and adipose
tissue (Gajdosechova et al., 2014). This study highlighted the
importance of the oxytocin system in the pathogenesis of obesity
and suggested oxytocinase inhibition to improve obesity-induced
metabolic disturbances. Several studies have examined the role
of IRAP in obesity and glucose handling using various animal
models. Results have revealed that insulin regulated traffic of
IRAP toward membrane fraction in adipocytes is disturbed by
monosodium glutamate-induced obesity (Alponti et al., 2015)
and IRAP deficiency in mice fed high-fat diet lead to prevention
of development of obesity (Niwa et al., 2015). On the other
hand, acute inhibition of IRAP aminopeptidase activity with
specific inhibitor, HFI-419, does not affect glucose homeostasis
in the streptozotocin-induced experimental rat model of diabetes
mellitus (Albiston et al., 2017). However, the effect of inhibitor
of aminopeptidase activity HFI-419 on the physiology of skeletal
muscle and adipose tissue in obese pre-diabetic Zucker rats has
not been examined yet. The main hypothesis of our study was that
prolonged treatment with IRAP inhibitor moderates oxytocin
degradation in tissues, normalizes plasma oxytocin level and
alleviates the obese phenotype in Zucker rats.
The aim of our study was to investigate the impact of HFI-
419 application on the (i) whole-body metabolic parameters,
(ii) expression of the markers of oxidative stress in skeletal
muscle and adipose tissue, and (iii) expression of the tissue-




Male Zucker fatty rats (fa/fa) were purchased from Harlan
(Udine, Italy). The animals were housed in a 12-h light/dark cycle
with access to water and standard diet ad libitum. At the age
of 34 weeks, the animals were divided into three groups. The
control group of lean (n = 6) as well as the control group of
obese (n = 6) rats received vehicle (30% cyclodextrin solution)
and the experimental group of obese rats (n = 6) received IRAP
inhibitor (HFI-419) (Merck KGaA, Darmstadt, Germany) in a
dose 29 µg/100 g body weight/day dissolved in 30% solution
of cyclodextrin) for two weeks via osmotic minipumps (ALZET,
CA, United States) implanted subcutaneously, as described
previously (Eckertova et al., 2011). After the minipumps were
implanted, the rats were housed two per cage and were separated
by a transparent barrier. On the 12th day, animals were
subjected to intraperitoneal glucose tolerance test (ipGTT). After
2 days of recovery, overnight-fasted animals were sacrificed by
decapitation at the age of 34 weeks. Experimental procedures
involving animals were approved by the Jagiellonian University
Ethical Committee on Animal Experiments and conformed to
Declaration of Helsinki.
Intraperitoneal Glucose Tolerance Test
The ipGTT was performed to assess glucose clearance.
Overnight-fasted rats were administered an intraperitoneal
injection of 50% glucose (w/v) at a dose of 2 g/kg body
weight. The blood glucose was measured in the tail vein
blood prior to and 30, 60, 90, and 120 min after glucose
administration using a glucometer (Accu-Check Active, Roche
Diagnostics, Switzerland).
Measurement of Selected Metabolic
Parameters and Hormones
After decapitation the trunk blood was collected in cooled tubes
containing EDTA as anticoagulant and centrifuged immediately
at 4◦C to separate plasma, which was stored in aliquots at−20◦C
until analyaed. Fasting plasma insulin level was measured using
commercial radioimmunoassay kit (Millipore, Bedford, MA,
United States) following the manufacturer’s protocol. Fasting
plasma glucose levels were measured using the multianalyser
COBAS Integra 800 (Roche Diagnostics Ltd., Rotkreuz,
Switzerland). Plasma lipid profile determination was performed
using commercially available kits (Roche Molecular Diagnostics,
Pleasenton, CA, United States). Quantitative insulin sensitivity
check index (QUICKI) was calculated as follows: inverse of
the sum of the logarithms of the fasting insulin (µU/ml) and
fasting glucose (mg/dl). Plasma oxytocin concentrations were
measured by EIA (Phoenix Pharmaceuticals, Burlingame, CA,
United States) after extraction of the peptides using C-18
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SEP COLUMN, following the manufacturer’s instructions.
Precision of the assay declared by the manufacturer is: intra-
assay variation <10%; inter-assay variation: <15%. Plasma
C-peptide 2 concentrations were measured by ELISA (EMD
Millipore Corporation, St. Louis, MO, United States) following
the manufacturer’s protocol.
RNA Isolation and Real-Time PCR
Prior to sampling for RNA, dissected samples from musculus
quadriceps and epididymal adipose tissues were removed, frozen
in liquid nitrogen and stored at –80◦C until analysis. Total RNA
was isolated using RNeasy Plus Universal Mini Kit (Qiagen,
Valencia, CA, United States) following the manufacturer’s
instructions. The reverse transcription of isolated RNA was
performed using Maxima First Strand cDNA Synthesis Kit
(Thermo Fisher, Waltham, MA, United States) according to
the manufacturer’s protocol. Real-time PCRs were carried out
applying Maxima SYBR Green qPCR Master Mix (Thermo
Fisher, Waltham, MA, United States) and run on an ABI 7900HT
thermal cycler (Applied Biosystems, Life Technologies, Carlsbad,
CA, United States) using rat-specific primer pairs as described
previously (Dobrocsyova et al., 2020). Data were normalized
to the expression of housekeeping gene ribosomal protein S29
(Rps29) which was not altered by the treatment.
Measurement of Enzyme Activity
Activity of glutamyl aminopeptidase was determined in
the membrane fraction. Skeletal muscle and epididymal
adipose tissue were homogenized using a glass Teflon
homogenizer in lysis buffer (250 mM saccharose, 10 mM
Tris, pH 7.4). The homogenates were centrifuged at
1,000 × g/10 min/4◦C. The supernatants were collected
and centrifuged at 16,000 × g/15 min/4◦C to separate the
membrane fraction. Protein concentration was measured by the
Bicinchoninic Acid Protein Assay (Sigma-Aldrich, St. Louis,
MO, United States). Prepared samples were mixed with substrate
solution containing 100mM H-Glu-β-naphthylamide (Bachem,
Bubendorf, Switzerland), 10 mg/100 ml bovine serum albumin,
10 mg/100 ml dithiothreitol, 50 mM CaCl2 in 50 mM Tris pH
7.4. The 96-well plate was placed in a Synergy H4 Hybrid Reader
(BioTek, Winooski, VT, United States) fluorimeter and the
enzyme kinetics was measured during 60 min at 37◦C with data
collection in 5-min intervals as the amount of β-naphthylamide
released from the substrate due to the enzyme activity of AP-A at
wavelengths 340 nm (excitation) and 410 nm (emission).
Superoxide dismutase activity was measured in skeletal
muscle tissue samples by colorimetric SOD Activity Assay Kit
(Abcam, Cambridge, United Kingdom). Tissue homogenization
and assay procedure were performed in accordance with the
manufacturer’ protocol.
Western Blot
Quadriceps muscle was homogenized as described previously
(Gajdosechova et al., 2014). After separation of proteins by SDS-
PAGE electrophoresis and theirs transfer to a PVDF membrane
(Immobilon-FL, Millipore, Bedford, MA, United States) the
blots were incubated with primary antibody overnight at
4◦C against insulin receptor substrate 1 (IRS-1) total protein
or its phosphorylated form at residue Ser307 and Ser612
(#2382, #2381, and #2386, respectively; all purchased in Cell
Signaling Technology, Danvers, MA, United States), insulin
receptor β (IRβ) total and phosphorylated IRβ at Tyr1150/1151
residue (#3025 and #3024, Cell Signaling Technology, Danvers,
MA, United States), SOD1, SOD2, NAD-dependent protein
deacetylase sirtuin-1 (SirT1) and GAPDH (#37385, #13141,
#9475, and #5174, respectively; Cell Signaling Technology,
Danvers, MA) diluted (1:1000) in blocking buffer containing
0.1% Igepal. After membrane washing, the signal of fluorescently
labeled secondary anti-rabbit IgG (#5151; Cell Signaling
Technology, Danvers, MA, United States) was detected using the
Odyssey infrared imaging system (LI-COR Biosciences, Lincoln,
NE, United States) and quantified by Odyssey IR imaging system
software version 2.0.
Statistical Analysis
The results are presented as mean ± SEM. Analysis of normally
distributed data was performed using the Kolmogorov-Smirnov
test. Non-normally distributed data were subjected to natural
logarithm transformation prior to statistical analysis. ANOVA
with repeated measures was used to analyze glycemia at different
time points of glucose tolerance test. Differences in basic
metabolic and morphometric parameters, hormone levels and
total area under the curve (AUC) for the glucose between
experimental groups were analyzed by one-way ANOVA and
differences between obese rats treated with vehicle and obese rats
treated with HFI-419 aimed at determing skeletal muscle and
adipose tissue metabolism were analyzed using Student’s t-test.
Overall level of statistical significance was reached at ∗p < 0.05,
∗∗p < 0.01, and ∗∗∗p < 0.001.
RESULTS
We determined the basic characteristics of systemic metabolic
and morphometric parameters in lean and obese Zucker rats
and obese Zucker rats treated with HFI-419 for two weeks.
As expected, obesity in Zucker (fa/fa) rats was accompanied
by an increase in plasma insulin, C-peptide 2, triglycerides,
cholesterol and LDL/HDL ratio, decreased insulin sensitivity
index (QUICKI) and plasma oxytocin level without significant
changes in fasting glycemia (Table 1). Plasma oxytocin
concentration displayed a strong tendency (p = 0.058) toward
increase after HFI-419 treatment. Two weeks administration of
HFI-419 had no statistically significant effect on obesity-induced
impaired metabolic and morphometric parameters (Table 1).
In order to determine the systemic effect of HFI-419 on
glucose utilization, we performed ipGTT (Figure 1). The
ANOVA with repeated measures revealed significant interaction
between time and group of rats (p < 0.001) and subsequent
post hoc analysis detected that HFI-419 treatment in obese rats
led to decline of blood glucose at 30 (p < 0.001), 60 (p < 0.001),
and 90 (p < 0.01) min after the glucose load when compared
with obese animals treated with vehicle (Figure 1A). Similar
marked tendency for 2-h glycemia to decrease (p = 0.065) was
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TABLE 1 | Metabolic parameters in lean and obese Zucker rats treated with vehicle and obese Zucker rats treated with HFI-419.
leanVEH (n = 6) obVEH (n = 6) obHFI-419 (n = 6) ANOVA p
Body weight (g) 419.2 ± 18.0 608.5 ± 33.3 *** 161.0 ± 9.5 *** <0.001
Fasting glycemia (mmol/l) 6.30 ± 0.20 6.48 ± 0.10 6.63 ± 0.27 0.523
Fasting insulin (ng/ml) 0.93 ± 0.20 10.91 ± 1.07 *** 11.66 ± 0.79 *** <0.001
C-peptide (pM) 266 ± 37 1745 ± 121 *** 1734 ± 87 *** <0.001
QUICKI# 0.294 ± 0.010 0.220 ± 0.002 *** 0.218 ± 0.002 *** <0.001
2-h glycemia (mmol/l) 5.97 ± 0.44 9.75 ± 0.61 *** 8.33 ± 0.30 *** 0.001
Triglycerides (mmol/l) 1.07 ± 0.07 3.54 ± 0.57 *** 4.21 ± 0.69 *** <0.001
Cholesterol (mmol/l) 2.48 ± 0.09 6.40 ± 0.41 *** 7.18 ± 0.70 *** <0.001
LDL/HDL 0.205 ± 0.015 0.418 ± 0.037 * 0.510 ± 0.108 * 0.005
Plasma oxytocin (pg/ml) 26.98 ± 8.50 2.88 ± 1.01 ** 7.79 ± 1.74 0.013
#QUICKI: quantitative insulin sensitivity check index. Data are presented as mean ± SEM and were analyzed using one-way ANOVA with Holm-Sidak post hoc test:
*p < 0.05, **p < 0.01, ***p < 0.001 vs. leanVEH.
observed after the treatment (Table 1). Calculated AUC for
glucose from ipGTT data was significantly reduced after HFI-419
administration (Figure 1B).
Regarding the insulin signaling pathway the protein
expression of total insulin receptor β subunit (IRβ) and
insulin receptor substrate (IRS-1) as well as phosphorylation
of IRS-1 at residue Ser307 and Ser612 and IRβ at residue
Tyr1150/1151 were evaluated in skeletal muscle. We did
not observe statistically significant differences in total IRβ
content (IRβ/GAPDH: Vehicle – 1.224 ± 0.092 vs. HFI-419 –
1.215 ± 0.127 a.u., p = 0.589) and total IRS-1 protein level (IRS-
1/GAPDH: Vehicle – 0.553 ± 0.084 vs. HFI-419 – 0.499 ± 0.063
a.u. p = 0.621) after HFI-419 administration. The ratios of
phospho-IRβ (Tyr1150/1151)/IRβ was significantly increased
by HFI-419 treatment while the phospho-IRS-1 (Ser307)/IRS-1
ratio was significantly reduced by IRAP inhibitor application
(Figures 1C,D). The ratio of phospho-IRS-1 (Ser612)/IRS-1
was unaffected by the treatment (Ser612)/IRS-1: Vehicle –
0.238± 0.039 vs. HFI-419 – 0.252± 0.030 a.u. p = 0.780).
The observed changes led us to an extensive investigation
of impact of HFI-419 treatment on insulin-responsive tissues
metabolism in obese Zucker rats. Regarding skeletal muscle
glutamyl aminopeptidase (AP-A), which is disregulated in
obesity, both Enpep mRNA level (Figure 1A) and AP-A activity
(Figure 2B) were significantly upregulated in this tissue in
obese Zucker rats after the treatment. AP-A activity in plasma
(Figure 2C) as well as epididymal adipose tissue (Figure 2D) was
not affected by HFI-419 administration.
Since hyperlipidemia-induced ROS production in skeletal
muscle is involved in inhibition of insulin action, we evaluated
the mRNA level of markers of oxidative stress and antioxidant
defence mechanism in this tissue as well as in epididymal adipose
tissue. In skeletal muscle, statistically significant upregulation
of Sod1 and Sod2 mRNA levels were detected after HFI-419
administration (Figure 3A). A similar stimulating effect of HFI-
419 was found in the case of SOD1 and SOD2 protein expression
and SOD enzyme activity (Figures 3C,D). The expression of
other genes encoding enzymes with antioxidant properties (Sod3,
Nfe2l2, and Nos3) and NOX4 and P22PHOX subunit of NADPH
oxidase (Nox4 and Cyba) were not significantly affected by the
treatment. In adipose tissue, the expression of prooxidant and
antioxidant genes was found unchanged except for Cyba mRNA
level, which tended to decrease (p = 0.07) in rats treated with
HFI-419 (Figure 3B).
In skeletal muscle, significantly elevated level of transcription
factor forkhead box protein O1 (Foxo1) mRNA, involved
in regulation of redox balance, were detected after HFI-419
treatment (Figure 3E). Interestingly, increased protein content of
SirT1, regulator of Foxo transcriptional activity, were observed
in skeletal muscle after HFI-419 administration (Figure 3C).
The gene expressions of transforming growth factor β-1 (Tgfb1),
peroxisome proliferator-activated receptor gamma coactivator 1-
α (Ppargc1a), involved in mitochondrial biogenesis, and type-2
angiotensin II receptor (Agtr2) were not changed in obese Zucker
rats receiving HFI-419 (Figure 3E).
Regarding the adipose tissue metabolism, the effect of HFI-
419 treatment on the gene expression of markers involved in
adipogenesis and inflammation were detected in epididymal fat
depot of obese Zucker rats. The Fabp4 mRNA level was not
changed while mesoderm-specific transcript homolog protein
(Mest) and plasminogen activator inhibitor 1 (Pai1) mRNA levels
were significantly reduced and C-C chemokine receptor type 2
(Ccr2) transcript level tended to decrease (p = 0.08) in HFI-419–
treated rats (Figure 3F).
DISCUSSION
The genetically obese Zucker rats (fa/fa) represent a model
of insulin resistance and prediabetes characterized by
hyperinsulinemia, hyperlipidemia and peripheral glucose
intolerance which is caused largely by an impairment of
insulin-stimulated glucose uptake into skeletal muscle, the
major site of insulin-mediated glucose disposal (Ionescu et al.,
1985; King et al., 1992). We and other authors have previously
shown that obesity is associated with dysregulation of IRAP
activity in adipose tissue and skeletal muscle along with reduced
plasma oxytocin due to increased peptide degradation by
peripheral tissues (Gajdosechova et al., 2014; Alponti et al.,
2015). A study on IRAP-knockout mice showed protective
effect of aminopeptidase deficiency against development of
obesity (Niwa et al., 2015). In order to investigate the impact
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FIGURE 1 | The effect of HFI-419 treatment on glucose utilization evaluated by intraperitoneal glucose tolerance test (ipGTT) in Zucker rats presented as absolute
glucose concentrations (A) and as area under the curve (AUC) (B). Data are shown as mean ± SEM and differences between experimental groups (n = 6) were
analyzed by ANOVA with repeated measurements (for glucose concentrations) and one-way ANOVA (for AUC) with subsequent Holm-Sidak multiple comparison:
*p < 0.05; **p < 0.01; ***p < 0.001 vs. lean vehicle group and ##p < 0.01; ###p < 0.001 vs obese vehicle group. The effect of HFI-419 treatment on
phosphorylation of IRβ subunit at residue Tyr1150/1151 (C) and IRS-1 at residue Ser307 (D) in skeletel muscle determined as ratio between phosphorylated and
total protein forms. Expressions of these proteins were evaluated by western blot and representative blots are shown at the panel (E). Results are presented as
mean ± SEM and differences between experimental groups (n = 6) were analyzed by Student’s t-test. *p < 0.05.
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FIGURE 2 | Aminopeptidase A (AP-A) activity and expression in peripheral tissues and plasma. (A) Gene expression of AP-A (coded by Enpep gene) in musculus
quadriceps determined by real-time PCR. Data were normalized to the housekeeping gene encoding 40S ribosomal protein S29 (Rps29) whose expression was not
significantly changed by the treatment. (C) AP-A activity in the plasma and in the membrane fractions isolated from (B) skeletal muscle and (D) epididymal adipose
tissue. Data are expressed as mean ± SEM Differences between vehicle – (n = 6) and HFI-419 – treated (n = 6) obese Zucker rats were analyzed by Student’s t-test:
*p < 0.05; **p < 0.01.
of IRAP inhibition on peripheral glucose tolerance and skeletal
muscle and adipose tissue metabolism, we treated obese
Zucker rats with HFI-419, a specific inhibitor of IRAP catalytic
activity, for 2 weeks.
In our study, we confirmed reduced plasma oxytocin levels
in obese eight-month-old rats compared with lean animals. The
inhibition of aminopeptidase activity by HFI-419 resulted in a
strong elevating tendency of circulating oxytocin level which was
accompanied with marked amelioration of the glucose utilization
during ipGTT in obese rats treated with IRAP inhibitor. Based
on decrease of AUC and 2-h glycemia (p = 0.065) to control
values in HFI-419 – treated rats, we assume that inhibition of
IRAP substantially improved glucose tolerance in obese rats.
Decreased blood glucose level at 30 min in obese treated rats
compared to both untreated obese and control lean rats during
ipGTT may indicate that the HFI-419 treatment could enhance
the insulin secretion after the glucose injection. However, plasma
insulin and C-peptide was not determined during ipGTT in
our study. Regarding peripheral glucose tolerance, our results
are consistent with previous observations in IRAP-deficient
mice (Irap-/-) in which glucose and insulin tolerance tests have
revealed that the glucose disposal and the hypoglycemic effect of
insulin did not differ between groups of animals fed a normal
diet but both of those are improved in Irap-/- mice after a
high-fat diet challenge (Niwa et al., 2015). On the contrary,
acute single administration of IRAP inhibitor HFI-419 did
not affect peripheral whole-body glucose handling during the
glucose and insulin tolerance tests, neither in control rats nor in
the streptozotocin-induced experimental rat model of diabetes
mellitus type I (Albiston et al., 2017). In keeping with these
results, IRAP in vitro inhibition (30-min and 24-h) of both
basal and insulin-stimulated L6GLUT4myc cells did not alter
glucose uptake (Albiston et al., 2017). Thus, the effect of HFI-
419 on glucose utilization seems to depend on metabolic status
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FIGURE 3 | Effect of HFI-419 treatment on expression of genes and proteins with pro-oxidant and antioxidant action and genes coding proteins involved in skeletal
muscle and adipose tissue metabolism. Gene expression of superoxide dismutase [Cu-Zn] (Sod1), superoxide dismutase [Mn] (Sod2), extracellular superoxide
dismutase [Cu-Zn] (Sod3), nuclear factor erythroid 2-related factor 2 (Nfe2l2), endothelial nitric oxid syntase (Nos3), NADPH oxidase (Nox4) and cytochrome b-245
light chain (Cyba), type-2 angiotensin II receptor (Agtr2), peroxisome proliferator-activated receptor gamma coactivator 1-α (Ppargc1a), forkhead box protein O1
(Foxo1), transforming growth factor β-1 (Tgfb1), fatty acid-binding protein 4 (Fabp4), mesoderm-specific transcript homolog protein (Mest), C-C chemokine receptor
type 2 (Ccr2) and plasminogen activator inhibitor 1 (Pai1) in musculus quadriceps (A,E) and epididymal adipose tissue (B,F) of vehicle– and HFI-419–treated obese
Zucker rats determined by real-time PCR. Data were normalized to the gene expression of 40S ribosomal protein S29 (Rps29) whose expression was not altered by
the treatment. Protein expression of SOD1 and SOD2 and silent information regulator 1 (SirT1) (C) and SOD activity (D) in skeletal muscle of obese vehicle– and
HFI-419–treated rats. Expression of proteins was evaluated by western blot and obtained data were normalized to loading control GAPDH whose expression was
not altered by the treatment. Representative blots are shown at the panel (G). SOD activity is expressed as percentage of inhibition of tetrazolium salt WST-1
conversion to formazan dye and is related to 1 mg of tissue. Data are presented as mean ± SEM and were analyzed by Student’s t-test: *p < 0.05; **p < 0.01.
Frontiers in Molecular Biosciences | www.frontiersin.org 7 December 2020 | Volume 7 | Article 586225
fmolb-07-586225 November 30, 2020 Time: 20:30 # 8
Krskova et al. IRAP Inhibition Ameliorates Metabolism in Obesity
of the animals with the positive effect seen only in obese and
insulin resistant ones.
With regard to potential mechanism for improvement
of glucose utilization in HFI-419–treated animals we found
beneficial changes in the insulin signaling cascade in the
skeletal muscle. The ratio of phospho-IRβ(Tyr1150/1151)/IRβ
was increased after HFI-419 administration. Insulin receptor
subunit β phosphorylation in the Tyr11501151 has been
demonstrated to be an important control site for transmission
of the insulin signal (White et al., 1988). Next we found
significantly decreased the ratio of phospho-IRS-1(Ser307)/IRS-
1 and unaffected phospho-IRS-1(Ser612)/IRS-1 ratio in skeletal
muscle of HFI-419–treated rats. Increased phosphorylation of
IRS-1 on residues Ser307 and Ser612 have been suggested to
be responsible for the desensitization mechanisms of insulin-
stimulated signal transduction which plays an important role
in insulin resistance in obesity (Aguirre et al., 2000). Thus, our
results suggest that IRAP inhibition has a beneficial effect on
glucose metabolism in the skeletal muscle.
We have recently detected obesity-associated significant
decrease of membrane-bound AP-A (glutamyl aminopeptidase)
activity in the skeletal muscle of Zucker rats accompanied
by elevated plasma AP-A activity suggesting stimulated tissue
AP-A autolysis due to dyslipidemia in obese phenotype (Lory
et al., 2019). AP-A hydrolyses angiotensin II to the heptapeptide
angiotensin III which has the highest relative affinity for AT2
receptor and is the most potent endogenous AT2 receptor agonist
(Bosnyak et al., 2011). After HFI-419 treatment, we found
a significant increase of AP-A gene expression along with a
significant increase of membrane-bound AP-A activity in skeletal
muscle. Such an upregulation of tissue AP-A activity was not
observed in the plasma implicating that IRAP inhibitor has the
potential to normalize obesity-impaired release of AP-A into the
circulation and normalize the levels of its soluble form. In our
previous study, we found a significant (10-fold) increase in AT2
receptor and a parallel decrease in AT1 receptor gene expression
in obese 8-month-old Zucker rats (Lory et al., 2019). Regarding
skeletal muscle physiology, AT2 receptor activation improves
skeletal muscle perfusion, glucose uptake and oxygenation and
is required for normal muscle microvascular and metabolic
responses to insulin (Chai et al., 2011).
In relation to hyperlipidemia-induced ROS production and
mitochondrial dysfunction associated with development of
insulin resistance in skeletal muscle, we evaluated expression of
genes encoding proteins with pro- and antioxidant properties and
found out that HFI-419 treatment elevates the Sod1 and Sod2
mRNA levels while the expression of prooxidative genes (Nox4
and Cyba) did not change. Increased superoxide dismutases gene
expressions were also reflected in an increase in the SOD1 and
SOD2 protein levels as well as in an increase in the SOD enzyme
activity in the treated animals. The first line of antioxidant
defense systems, critical in maintaining cellular redox balance,
consists of superoxide dismutases (SODs), which eliminates
superoxide to produce the less reactive H2O2: the cytosolic
Cu/Zn-containing SOD (CuZnSOD encoded by Sod1 gene), the
mitochondrial Mn-containing SOD (MnSOD encoded by Sod2
gene), and the extracellular SOD (EcSOD encoded by Sod3 gene)
(Di Meo et al., 2017). Several lines of evidence have been provided
that Sod1 overexpression improves insulin-dependent glucose
uptake into cells as well as peripheral glucose tolerance (Hoehn
et al., 2009; Boden et al., 2012). Furthermore, MnSOD −/+mice
displayed a significant impairment in glucose tolerance despite
similar insulin levels to control mice (Hoehn et al., 2009). This
upregulation of Sod1 and Sod2 genes observed in our study
indicate that HFI-419 treatment has a beneficial effect on the
skeletal muscle redox homeostasis, which is reflected by the
improved glucose utilization. The up-regulation of antioxidant
enzymes SOD1 and SOD2 observed in our study suggests that
HFI-419 treatment has an improving effect on the skeletal muscle
redox homeostasis, which might contribute to skeletal muscle
insulin sensitivity.
A novel observation of the present study is that IRAP
inhibition induced an elevation of Foxo1 mRNA, transcription
factor highly expressed in the major insulin target tissues, as well
as protein content of SirT1, regulator of FoxO transcriptional
activity in skeletal muscle of obese rats. It has been shown,
that under pathophysiological conditions such insulin resistance
and metabolic dysfunction FoxO1 expression may help drive
the expression of genes involved in combating oxidative stress
and that there is interplay between SirT1 and FoxO in ROS
reduction. SirT1 also directly interacts with SOD, which could
be regulated through FoxO (Gross et al., 2008; Zhang et al.,
2017). It is tempting to speculate, that HFI-419–induced up-
regulation of SirT1 protein may be involved in subsequent SOD
upregulation and amelioration of oxidative stress in skeletal
muscle of obese Zucker rats.
In relation to adipose tissue metabolism, plasminogen
activator inhibitor 1 (PAI-1), a key component of fibrinolysis
that has been demonstrated within adipose tissue being involved
in adipose tissue expansion and insulin resistance was found to
be reduced at the mRNA level after treatment with HFI-419.
Study using Irap-/- mice revealed that IRAP deficiency may lead
to attenuated PAI-1 expression in differentiated preadipocytes
isolated from inguinal fat pads of mice, since adipocyte Pai1
mRNA as well as PAI-1 protein and its secretion into the culture
medium were lower in adipocytes from Irap-/- mice than those
of wild-type mice (Wang et al., 2018). PAI-1 also contributes
to the development of inflammation in adipose tissue during
obesity by mechanism involving up-regulation of M1 (clasically
activated) macrophage numbers in visceral adipose depot (Wang
et al., 2018). In addition to down-regulated Pai1 mRNA in our
study, the gene expression of C-C chemokine receptor type
2 (Ccr2), a marker of adipose tissue macrophage infiltration
and accumulation (Kim et al., 2016), and mesoderm-specific
transcript homolog protein (Mest), displayed clear tendency to
decline by HFI-419 application. MEST is thought to play a
role in the facilitation of lipid accumulation and fat storage in
adipocytes, adipogenesis and adipocyte hypertrophy (Takahashi
et al., 2005; Prudovsky et al., 2018). Our study confirmed in vivo
previously observed in vitro changes in PAI-1 and has showed a
role for IRAP in the regulation of these adipocyte markers.
In summary, our results show that the specific inhibitor
of aminopeptidase activity of IRAP, HFI-419, ameliorated the
obesity-induced metabolic disturbances in in obese Zucker
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rats. Beneficial effect was manifested by improvement of the
peripheral whole-body glucose tolerance as well as activation of
skeletal muscle antioxidant mechanisms and insulin signaling
pathway. The results presented are likely to motivate further
research as there is a gap in the knowledge regarding
the regulation of IRAP/oxytocinase in order to reveal new
approaches to modulate metabolism in obesity.
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(2019). Obesity and aging affects skeletal muscle renin-angiotensin system and
myosin heavy chain proportions in pre-diabetic Zucker rats. J. Physiol. Biochem.
75, 351–365. doi: 10.1007/s13105-019-00689-1
Morais, R. L., Hilzendeger, A. M., Visniauskas, B., Todiras, M., Alenina, N., Mori,
M. A., et al. (2017). High aminopeptidase A activity contributes to blood
pressure control in ob/ob mice by AT2 receptor-dependent mechanism. Am.
J. Physiol. Heart Circ. Physiol. 312, H437–H445.
Niwa, M., Numaguchi, Y., Ishii, M., Kuwahata, T., Kondo, M., Shibata, R.,
et al. (2015). IRAP deficiency attenuates diet-induced obesity in mice through
increased energy expenditure. Biochem. Biophys. Res. Commun. 457, 12–18.
doi: 10.1016/j.bbrc.2014.12.071
Frontiers in Molecular Biosciences | www.frontiersin.org 9 December 2020 | Volume 7 | Article 586225
fmolb-07-586225 November 30, 2020 Time: 20:30 # 10
Krskova et al. IRAP Inhibition Ameliorates Metabolism in Obesity
Phillips, M. S., Liu, Q., Hammond, H. A., Dugan, V., Hey, P. J., Caskey, C. J., et al.
(1996). Leptin receptor missense mutation in the fatty Zucker rat. Nat. Genet.
13, 18–19. doi: 10.1038/ng0596-18
Prudovsky, I., Anunciado-Koza, R. P., Jacobs, C. G., Kacer, D., Siviski, M. E., Koza,
R. A., et al. (2018). Mesoderm-specific transcript localization in the ER and ER-
lipid droplet interface supports a role in adipocyte hypertrophy. J. Cell Biochem.
119, 2636–2645. doi: 10.1002/jcb.26429
Ritchie, S. A., and Connell, J. M. (2007). The link between abdominal
obesity, metabolic syndrome and cardiovascular disease. Nutr.
Metab. Cardiovasc. Dis. 17, 319–326. doi: 10.1016/j.numecd.2006.
07.005
Takahashi, M., Kamei, Y., and Ezaki, O. (2005). Mest/Peg1 imprinted gene enlarges
adipocytes and is a marker of adipocyte size. Am. J. Physiol. Endocrinol. Metab.
288, E117–E124.
Wang, L., Chen, L., Liu, Z., Liu, Y., Luo, M., Chen, N., et al. (2018). PAI-1
exacerbates white adipose tissue dysfunction and metabolic dysregulation in
high fat diet-induced obesity. Front. Pharmacol. 9:1087. doi: 10.3389/fphar.
2018.01087
White, M. F., Shoelson, S. E., Keutmann, H., and Kahn, C. R. (1988). A
cascade of tyrosine autophosphorylation in the beta-subunit activates the
phosphotransferase of the insulin receptor. J. Biol. Chem. 263, 2969–2980.
Zhang, W., Huang, Q., Zeng, Z., Wu, J., Zhang, Y., Chen, Z., et al. (2017). Sirt1
inhibits oxidative stress in vascular endothelial cells. Oxid. Med. Cell Longev.
2017:7543973.
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Krskova, Balazova, Dobrocsyova, Olszanecki, Suski, Chai and
Zorad. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in
other forums is permitted, provided the original author(s) and the copyright owner(s)
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Molecular Biosciences | www.frontiersin.org 10 December 2020 | Volume 7 | Article 586225
